Andrea Lobo,  —

Low levels of PM20D1, a molecule involved in metabolizing lipids, were identified as a risk factor for mortality in people with pulmonary arterial hypertension (PAH), a study reports. As a result, PM20D1, or peptidase M20 domain containing 1, may be a biomarker of disease prognosis, according to scientists. Lipid…

Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in people with HIV-1 infection in a bioinformatics study, offering new perspectives to uncover the underlying molecular mechanisms that link HIV infection and PAH. The genes ISG15 and IFI27 are established hub genes involved in the type…

Low levels of circular RNA Alstrom syndrome protein 1, or circALMS1, may be associated with poor outcomes with pulmonary hypertension (PH), a study suggests. This may be because low circALMS1 levels promote higher numbers and the migration of pulmonary microvascular endothelial cells (PMECs), and reduce the cells’ death. PMECs…

Most people with pulmonary arterial hypertension (PAH) due to connective tissue disease (CTD) who are using Opsumit (macitenan) do so as part of a combination therapy, according to real-world evidence from two U.S. drug registry studies. Its safety and effectiveness, in terms of clinical outcomes, for these patients…

Having pulmonary hypertension (PH) worsens the likelihood of potentially life-threatening cardiac and respiratory complications in people with human immunodeficiency virus (HIV) infection, a U.S. database study reported. Its findings “can inform clinical practice and help healthcare providers make more informed decisions regarding the screening, diagnosis, and management of PH…

Blood levels of microRNA — small RNA molecules that regulate protein production — are decreased in people with pulmonary embolism (PE) compared with healthy people. PE is the cause of chronic thromboembolic pulmonary hypertension (CTEPH). However, higher blood levels of miR-let7a were found in people with acute PE who…

Despite having more favorable clinical measures, such as blood flow, men with pulmonary arterial hypertension (PAH) have a higher mortality risk than women with the disease, according to a recent study. This is known as the “sex paradox” and may occur because men may develop PAH only if higher…

Gradient Denervation Technologies has enrolled the first patient in a clinical study of an ultrasound-based catheter device for the treatment of pulmonary hypertension (PH) caused by left heart disease. The PreVail-PH2 (NCT06052072) study is evaluating the feasibility of the minimally invasive device in delivering therapeutic ultrasound energy…

Tenax Therapeutics has secured global rights to oral and subcutaneous (under the skin) formulations of levosimendan, a potential therapy for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Under a licensing agreement established with Orion Corp. in 2013, Tenax acquired developmental and commercial rights of…

People with pulmonary hypertension (PH) and high blood acetylcholine (ACh) levels show more severe symptoms and a poorer prognosis than those with lower ACh levels, a single-center study in China suggests. ACh is a neurotransmitter, a chemical messenger that allows nerve cells to communicate…

The first healthy volunteer has been dosed in a Phase 1 trial testing ZMA001, Zymedi’s first-in-class investigational therapy for pulmonary arterial hypertension (PAH). The trial (NCT05967299), still recruiting participants at a clinical center in Bethesda, Maryland, will evaluate the safety, tolerability, and pharmacological properties of ZMA001.

Access to pulmonary rehabilitation programs for people with pulmonary hypertension (PH) and other chronic respiratory conditions is considerably more difficult for those living in rural U.S. regions than in urban areas, scientists report. Travel longer than 60 minutes affects more than 14 million U.S. residents of rural or underpopulated…